OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance

– Q2 revenue totals $20.5 million – Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively – Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million – Completed debt refinancing with $35 million traditional